AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019
Dec 30, 2019
31580_dirs_2019-12-30_c552938b-b416-4be7-b7ae-d18f9df568d8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2019-12-26
Reporting Person: Alenson Carman (Principal Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-12-26 | Common stock | S | 2950 | $50.09 | Disposed | 184 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.04 to $50.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Includes shares purchased through the Company's employee stock purchase plan.